Why is PT-141 not working?

The approved trials measured a modest average effect in a specific population, not a guarantee for every user. RECONNECT tested 1.75 milligrams as needed in 1,267 premenopausal women with hypoactive sexual desire disorder over 24 weeks: desire scores rose by 0.35 on the integrated FSFI desire scale versus placebo, with nausea, flushing, and headache each in 10% or more. The 52-week extension in 684 women was open-label safety, so it cannot show that the effect still beats placebo. Use in men is off label. This site holds no citation that explains why a given person would feel nothing.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of names, absences, and legal limits. Brand versus molecule, side effects this site's citations did not measure, how long the trials actually ran, what national legal-status fields can say, and why two-compound answers do not scale to a larger stack.